13th Apr 2016 07:00
Premaitha Health plc
("Premaitha" or the "Company")
Holdings in Company, Director's Shareholding
& Concert Party Disclosure
Manchester, UK - 13 April 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening system, was informed on 12 April 2016 that, on the same day, Zoragen Biotechnologies LLP, Loxbridge Research LLP and Rupert Lywood disposed of their entire shareholdings of 29,373,230 ordinary shares, 9,284,264 ordinary shares and 2,160,000 ordinary shares respectively.
The 40,817,494 ordinary shares have been placed by the Company's joint broker, finnCap, to meet demand from institutions and from a director of the Company (the "Placing"). Following the Placing, the issued share capital of the Company remains unchanged at 228,163,709 ordinary shares of 10 pence each.
Director's Shareholding
Adam Reynolds, a director of the Company, acquired 380,000 ordinary shares in the Placing at a price of 6.5 pence per share. As a result, Mr Reynolds' shareholding in the Company has increased to 3,681,137 ordinary shares, representing 1.61% of the issued share capital.
Concert Party Disclosure
Following the trading of shares as detailed above, the shareholdings of members of the concert party in the Company are as follows:
Shareholding | % | Number of options held | Maximum potential shareholding
| % | |
Zoragen Biotechnologies LLP | - | - | - | - | - |
Animatrix Capital LLP | - | - | - | - | - |
Loxbridge Research LLP | - | - | - | - | - |
Rupert Lywood | - | - | - | - | - |
Stuart Lawson | - | - | - | - | - |
Charles Roberts | 6,339,546 | 2.8% | - | 6,339,546 | 2.5% |
David Evans | 3,540,636 | 1.6% | - | 3,540,636 | 1.4% |
Stephen Little* | 3,472,727 | 1.5% | 10,555,984 | 14,028,711 | 5.6% |
Peter Collins | 3,522,727 | 1.5% | 5,638,174 | 9,160,901 | 3.6% |
William Denman | 250,000 | 0.1% | 2,654,989 | 2,904,989 | 1.2% |
Michael Risley | 15,000 | 0.0% | 2,654,989 | 2,669,989 | 1.1% |
Rachel Shelmerdine | 15,000 | 0.0% | 1,055,598 | 1,055,598 | 0.4% |
NWF | 4,545,455 | 2.0% | - | 4,545,455 | 1.8% |
Adam Reynolds | 3,681,137 | 1.6% | 591,666 | 4,272,803 | 1.7% |
Total | 25,382,228 | 11.1% | 23,151,400 | 48,518,628 | 19.3% |
* In addition to the options set out above (all of which were subject to the waiver of the obligations of Rule 9 of the Takeover Code ("Rule 9") at the time of the Company's admission to AIM in July 2014), Stephen Little holds an additional 1,500,000 options (as announced on 15 July 2015) that have not been waived from the obligations of Rule 9.
For more information, please contact: For more information, please contact:
Premaitha Health plc | Tel: +44 (0) 161 667 6865 |
Dr Stephen Little, Chief Executive Office |
|
Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing |
|
| |
|
|
Cairn Financial Advisers LLP (Nomad) | Tel: +44 (0) 20 7148 7900 |
Liam Murray |
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) | Tel: +44 (0) 20 7886 2500 |
Robert Naylor (Corporate Finance) / Maisie Rose Atkinson (Sales) |
|
|
|
finnCap (Joint Broker) | Tel: +44 (0) 20 7220 0500 |
Adrian Hargrave / Scott Mathieson (Corporate Finance) |
|
Tony Quirke (Corporate Broking) |
|
|
|
Vigo Communications | Tel: +44 (0) 20 7830 9700 |
Ben Simons / Fiona Henson |
|
|
About Premaitha
Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.
Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's complete CE Marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening system in-house.
Premaitha is based in Manchester Science Partnerships, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.
Related Shares:
YGEN.L